Minireviews
Copyright ©The Author(s) 2022.
World J Clin Oncol. Sep 24, 2022; 13(9): 729-737
Published online Sep 24, 2022. doi: 10.5306/wjco.v13.i9.729
Table 1 Incidence and definition of hyperprogressive disease in advanced gastric cancer patients receiving immunotherapy
Study agent
Tumor
HPD definition
Number of patients
Incidence of HPD, %
Ref.
NivolumabAGC(1) An increase of ≥ 50% in the sum of longest diameter (SLD) of target lesions at 8 wk post baseline; (2) An increase of ≥ 20% in the sum of longest diameter of target lesions at 8 wk post baseline; and (3) An increase of ≥ 100% in the sum of longest diameter of target lesions at 8 wk post baseline243; 243; 2435.4; 27.6; 1.2Feng et al[75], 2018
PD-1 inhibitor monotherapyAGCTGKPOST⁄TGKPRE ≥ 2955.6Sugimoto et al[76], 2018
PD-1 inhibitor monotherapyAGCTGRPOST⁄TGRPRE ≥ 210524.8Sunakawa et al[77], 2019
PD-1 inhibitor monotherapyAGCTGRPOST⁄TGRPRE ≥ 221817.4Suzuki et al[78], 2020